NCCN guidelines recommend annual mammograms to detect disease recurrence, but according to the study’s findings, women — even those who had adequate health insurance — were less likely to have their once-a-year mammogram as they became long-term survivors.
The findings of a new study show that women with young children have concerns that affect emotional well-being.
Don't be scared to write "legacy letters." Here's advice on getting started and why it matters from a woman with metastatic breast cancer
One breast cancer survivor's thoughts on news from a recent study about the potential risks of surgery.
What it's like to live in a world that includes me, yet somehow keeps me out.
When roles change over time, use your cancer super powers to help, says melanoma and breast cancer survivor Barbara Tako.
In this episode, we’ll talk with founder Donna Deegan herself about the foundation and its efforts, as well as the foundation’s executive director Amanda Napolitano on how much they have raised so far, and we’ll hear from one very inspiring participant Hollis Youngner.
There are ways to bring a sense of belonging back to your world.
Findings from a new study presented at the American College of Cardiology’s 67th Annual Scientific Session showed that adding two popular heart medications to the chemotherapy regimen may prevent heart damage from happening in these patients.
This survivor regrets not being there when her mother passed away from metastatic breast cancer.
Breast cancer survivor's questions about genetic testing are ahead of the research.
The DONNA Foundation hosted its 11th annual marathon weekend in support of research and providing financial assistance to women with breast cancer.
How we think about things can have a powerful impact on our experiences. Here's why that matters for people with cancer.
The Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) for use in combination with a hormonal therapy for initial treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
Using some simple reminders that life is still happening can help put cancer anxiety and fear back where they belong.
Individual advocates and larger organizations offer hope as they help us understand what future treatments are in the pipeline.
Until recently, Herceptin, which is used to treat patients with metastatic breast cancer, was fully covered under Humana’s South Florida Medicare Advantage plans. But, after taking it off the preferred drug list, patients will now be responsible for 20 percent of the drug’s cost, better aligning South Florida’s plans with Humana’s other Medicare Advantage plans.
As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.
Lynparza (olaparib) was granted approval by the Food and Drug Administration (FDA) for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Also, patients who have HR-positive disease should have prior endocrine therapy or they would not be considered appropriate for such treatment.
